Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 87.50% and 36.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Illumina (ILMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Centene (CNC) Expands Evolent Partnership to Boost Quality
by Zacks Equity Research
Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.
HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza
by Zacks Equity Research
HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV
by Zacks Equity Research
Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 9.09% and 8.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
by Zacks Equity Research
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 72.7% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 76.32% and 12.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.
What Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for "Trend Investing"
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 106% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 106% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See an 114% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 113.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 151% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 150.6% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.